Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo

Umesh A. Badrising; Marion L. C. Maat-Schieman; Michel D. Ferrari; Aeilko H. Zwinderman; Judith A. M. Wessels; Ferdinand C. Breedveld; Pieter A. van Doorn; Baziel G. M. van Engelen; Jessica E. Hoogendijk; Chris J. Höweler; Aeiko E. de Jager; Frans G. I. Jennekens; Peter J. Koehler; Marianne de Visser; Alain Viddeleer; Jan J. Verschuuren; Axel R. Wintzen

doi:https://doi.org/10.1002/ana.10121

Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo

Umesh A. Badrising, Marion L. C. Maat-Schieman, Michel D. Ferrari, Aeilko H. Zwinderman, Judith A. M. Wessels, Ferdinand C. Breedveld, Pieter A. van Doorn, Baziel G. M. van Engelen, Jessica E. Hoogendijk, Chris J. Höweler, Aeiko E. de Jager, Frans G. I. Jennekens, Peter J. Koehler, Marianne de Visser, Alain Viddeleer, Jan J. Verschuuren, Axel R. Wintzen

Research output: Contribution to journal › Article › Academic › peer-review

113 Citations (Scopus)

Abstract

We investigated whether 5 to 20mg per week oral methotrexate could slow down disease progression in 44 patients with inclusion body myositis in a randomized double-blind placebo-controlled study over 48 weeks. Mean change of quantitative muscle strength testing sum scores was the primary study outcome measure. Quantitative muscle strength testing sum scores declined in both treatment groups, -0.2% for methotrexate and -3.4% for placebo (95% confidence interval = -2.5% to +9.1% for difference). There were also no differences in manual muscle testing sum scores, activity scale scores and patients' own assessments after 48 weeks of treatment. Serum creatine kinase activity decreased significantly in the methotrexate group. We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity

Original language	English
Pages (from-to)	369-372
Journal	Annals of neurology
Volume	51
Issue number	3
DOIs	https://doi.org/10.1002/ana.10121
Publication status	Published - 2002

Access to Document

https://doi.org/10.1002/ana.10121

Cite this

Badrising, U. A., Maat-Schieman, M. L. C., Ferrari, M. D., Zwinderman, A. H., Wessels, J. A. M., Breedveld, F. C., van Doorn, P. A., van Engelen, B. G. M., Hoogendijk, J. E., Höweler, C. J., de Jager, A. E., Jennekens, F. G. I., Koehler, P. J., de Visser, M., Viddeleer, A., Verschuuren, J. J., & Wintzen, A. R. (2002). Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Annals of neurology, 51(3), 369-372. https://doi.org/10.1002/ana.10121

@article{a254e6b022f84130bf4f7c16999a501d,

title = "Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo",

abstract = "We investigated whether 5 to 20mg per week oral methotrexate could slow down disease progression in 44 patients with inclusion body myositis in a randomized double-blind placebo-controlled study over 48 weeks. Mean change of quantitative muscle strength testing sum scores was the primary study outcome measure. Quantitative muscle strength testing sum scores declined in both treatment groups, -0.2% for methotrexate and -3.4% for placebo (95% confidence interval = -2.5% to +9.1% for difference). There were also no differences in manual muscle testing sum scores, activity scale scores and patients' own assessments after 48 weeks of treatment. Serum creatine kinase activity decreased significantly in the methotrexate group. We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity",

author = "Badrising, {Umesh A.} and Maat-Schieman, {Marion L. C.} and Ferrari, {Michel D.} and Zwinderman, {Aeilko H.} and Wessels, {Judith A. M.} and Breedveld, {Ferdinand C.} and {van Doorn}, {Pieter A.} and {van Engelen}, {Baziel G. M.} and Hoogendijk, {Jessica E.} and H{\"o}weler, {Chris J.} and {de Jager}, {Aeiko E.} and Jennekens, {Frans G. I.} and Koehler, {Peter J.} and {de Visser}, Marianne and Alain Viddeleer and Verschuuren, {Jan J.} and Wintzen, {Axel R.}",

year = "2002",

doi = "https://doi.org/10.1002/ana.10121",

language = "English",

volume = "51",

pages = "369--372",

journal = "Annals of neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

Badrising, UA, Maat-Schieman, MLC, Ferrari, MD, Zwinderman, AH, Wessels, JAM, Breedveld, FC, van Doorn, PA, van Engelen, BGM, Hoogendijk, JE, Höweler, CJ, de Jager, AE, Jennekens, FGI, Koehler, PJ, de Visser, M, Viddeleer, A, Verschuuren, JJ & Wintzen, AR 2002, 'Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo', Annals of neurology, vol. 51, no. 3, pp. 369-372. https://doi.org/10.1002/ana.10121

TY - JOUR

T1 - Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo

AU - Badrising, Umesh A.

AU - Maat-Schieman, Marion L. C.

AU - Ferrari, Michel D.

AU - Zwinderman, Aeilko H.

AU - Wessels, Judith A. M.

AU - Breedveld, Ferdinand C.

AU - van Doorn, Pieter A.

AU - van Engelen, Baziel G. M.

AU - Hoogendijk, Jessica E.

AU - Höweler, Chris J.

AU - de Jager, Aeiko E.

AU - Jennekens, Frans G. I.

AU - Koehler, Peter J.

AU - de Visser, Marianne

AU - Viddeleer, Alain

AU - Verschuuren, Jan J.

AU - Wintzen, Axel R.

PY - 2002

Y1 - 2002

N2 - We investigated whether 5 to 20mg per week oral methotrexate could slow down disease progression in 44 patients with inclusion body myositis in a randomized double-blind placebo-controlled study over 48 weeks. Mean change of quantitative muscle strength testing sum scores was the primary study outcome measure. Quantitative muscle strength testing sum scores declined in both treatment groups, -0.2% for methotrexate and -3.4% for placebo (95% confidence interval = -2.5% to +9.1% for difference). There were also no differences in manual muscle testing sum scores, activity scale scores and patients' own assessments after 48 weeks of treatment. Serum creatine kinase activity decreased significantly in the methotrexate group. We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity

AB - We investigated whether 5 to 20mg per week oral methotrexate could slow down disease progression in 44 patients with inclusion body myositis in a randomized double-blind placebo-controlled study over 48 weeks. Mean change of quantitative muscle strength testing sum scores was the primary study outcome measure. Quantitative muscle strength testing sum scores declined in both treatment groups, -0.2% for methotrexate and -3.4% for placebo (95% confidence interval = -2.5% to +9.1% for difference). There were also no differences in manual muscle testing sum scores, activity scale scores and patients' own assessments after 48 weeks of treatment. Serum creatine kinase activity decreased significantly in the methotrexate group. We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity

U2 - https://doi.org/10.1002/ana.10121

DO - https://doi.org/10.1002/ana.10121

M3 - Article

C2 - 11891832

SN - 0364-5134

VL - 51

SP - 369

EP - 372

JO - Annals of neurology

JF - Annals of neurology

IS - 3

ER -